AbbVie said that for the 9 months ended September 30, 2025, it recorded worldwide net revenues of $44.5 billion, operating earnings of $10.5 billion, diluted earnings per share of $1.34 and cash flows from operations of $13.8 billion. Net revenues increased 8% on both a reported basis and on a constant currency basis.

1. 01

   AbbVie said that for the 9 months ended September 30, 2025, it recorded worldwide net revenues of $44.5 billion, operating earnings of $10.5 billion, diluted earnings per share of $1.34 and cash flows from operations of $13.8 billion. Net revenues increased 8% on both a reported basis and on a constant currency basis.

2. 02

   AbbVie said that on a constant currency basis, Skyrizi net revenues increased 58% and Rinvoq increased 43% for the 9 months, while Humira decreased 55%. The company cited the continued impact of direct biosimilar competition following the loss of exclusivity as a factor in the Humira decline.

3. 03

   AbbVie said that its 9-month results included amortization of intangible assets of $5.6 billion, a change in fair value of contingent consideration liabilities of $5.1 billion and intangible asset impairment expense of $847 million. The company explained that the change in fair value reflected the passage of time, lower discount rates and higher estimated Skyrizi sales.

4. 04

   AbbVie said it paid cash dividends of $8.7 billion for the 9 months of 2025. On October 31, 2025, the board of directors increased the quarterly dividend from $1.64 per share to $1.73 per share, effective with the dividend payable on February 17, 2026.

Key figures

Quarter ended September 30, 2025

Revenue

$15.8B

Operating income

$1.9B

Net income

$186M

EPS

$0.10

Analysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.